Figure 6: Plasma clearance of glyco-modified pertuzumab in mice.

For the measurement of plasma clearance for glyco-modified pertuzumabs in mice, male ICR mice (n = 5) were injected intravenously with antihuman HER2 antibodies. The concentrations of antibodies in serum were measured by HER2 specific ELISA. The serum half-life was analyzed from the elimination phase. Pertuzumab^Fuc+SA+ type (black dotted line), pertuzumab^Fuc−SA+ type (red dotted line), pertuzumab^Fuc+SA− type (yellow dotted line), pertuzumab^Fuc−SA− type (green dotted line), pertuzumab^Fuc+SA− type + asialofetuin (blue dotted line) and pertuzumab^Fuc+SA− type + asialofetuin (pink dotted line). Data are representative of three independent experiments with similar results. Fuc: fucose, SA: Sialic acid.